

Topical Collection

Carcinogenesis Model

Message from the Collection Editor

Accumulated genetic alterations can initiate and drive carcinogenesis, which are subjected to promotion by epigenetic changes through interactions with many different types of cells in the tissue microenvironment. By genetic engineering and/or chemical treatments, researchers have created many in vivo animal models, which successfully recapitulated multistep carcinogenesis from normal cells to premalignant lesions, full-blown tumors and metastases. In light of such rapid advances in the field of carcinogenesis models, we need to put together various different types of models -including those generated by conventional or novel methods- to further promote cancer research. In this special issue of *Cancers*, we welcome original research articles or comprehensive review articles focusing on development of, or by using, any types of models reflecting any steps of carcinogenesis, in any species or organs. I hope that such collection of studies will further increase our knowledge on carcinogenesis and provide powerful tools to fight against cancer.

- tumorigenesis, models
- genetically engineered mouse (GEM)
- chemical carcinogenesis

Collection Editor

Dr. Yoshitaka Hippo

Division of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, 666-2, Nitona-cho, Chuo-ku, Chiba-city, Chiba 260-8717, Japan



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/31593

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)